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Abstract Almost 7 % of breast cancers are diagnosed
among women age 40 years and younger in Western
populations. Clinical outcomes among young women are
worse. Early age-of-onset increases the risk of contralateral
breast cancer, local and distant recurrence, and subsequent
mortality. Breast cancers in young women (BCYW) are
more likely to present with triple-negative (TNBC), TP53-
positive, and HER-2 over-expressing tumors than among
older women. However, despite these known differences in
breast cancer outcomes and tumor subtypes, there is limited
understanding of the basic biology, epidemiology, and
optimal therapeutic strategies for BCYW. Several modifi-
able lifestyle factors associated with reduced risk of
developing breast cancer have also been implicated in
improved prognosis among breast cancer survivors of all
ages. Given the treatment-related toxicities and the
extended window for late effects, long-term lifestyle
modifications potentially offer significant benefits to
BCYW. In this review, we propose a model identifying
three main areas of lifestyle factors (energy imbalance,
inflammation, and dietary nutrient adequacy) that may
influence survival in BCYW. In addition, we provide a
summary of mechanisms of action and a synthesis of pre-
vious research on each of these topics.
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Introduction
Breast cancer is the most common cancer among women in
Western populations with a lifetime cumulative incidence
probability of one in nine [1]. Approximately 6.6 % of
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younger. The average risk of developing breast cancer by
age 40 is one in 173 [1, 2]. Of all cancers diagnosed among
women by age 40 years, 40 % are breast cancers. Tradi-
tionally, breast cancers in young women (BCYW) have
been thought to be etiologically driven primarily by
genetic/hereditary factors [3]. BCYW are more likely to be
associated with increased familial risk, but only a relatively
small proportion of cases (\10 %) are attributable to
inherited germline variations in the known familial breast
cancer risk genes (BRCA1/BRCA2) [4, 5] and are highest in
those women with very strong family histories of breast or
ovarian cancer [5]. Other genomic factors, including
mutations in tumor suppressor and oncogenes, copy num-
ber variation, and epigenetics, are likely implicated in
cancer initiation and progression among young women.
However, these alterations do not fully explain carcino-
genesis and subsequent progression among young women.
There are four clinically relevant breast cancer phenotypes
currently recognized [6]: luminal A (ER?, PR?, HER2-,
Ki67 low), luminal B (ER?, HER2-, PR-, or Ki67 high),
triple-negative breast cancer (TNBC; ER-, PR-, and
HER2-), and HER2 over-expressing tumors (HER2?). The
TNBC andHER2? subtypes are themost aggressive forms of
breast cancer and are over-represented in BCYW [7–9].
Approximately 26 %ofBCYWare TNBCcompared to 12 %
overall [10, 11]. Next-generation sequencing of TNBC has
suggested that actionable mutations occur in only a small
subset (\20 %) of these cancers [12] and do not completely
predict survival [13]. Therefore, non-genomic factors,
including lifestyle and other epidemiologic factors, may sig-
nificantly impact recurrence and survival in BCYW.
Here we present a review of the epidemiologic literature
on the associations between lifestyle factors, recurrence, and
survival for BCYW, defined as a breast cancer diagnosed by
age 40 years. The aim of this review is to provide an over-
view of the associations observed to date among BCYW and
how they compare to those that have been observed in the
general population of breast cancer survivors. In doing so,we
have also aimed to identify gaps in the literature where
additional research is needed in this population. BCYW is
considered to be distinct from pre-menopausal breast cancer
(average age at menopause among North American women
is 51 years) [14, 15]. However, since there is limited epi-
demiologic research specifically examining the effect of
candidate risk factors on BCYW, we have included studies
on pre-menopausal cases if no BCYW-specific data were
available. We propose a biologic model for the impact of
selected lifestyle factors on prognosis in BCYW (Fig. 1). In
doing so, we provide a conceptual model for the inter-play
between these factors and their possible role in cancer pro-
gression. We have focused our review on modifiable factors
for which, despite evidence for an impact among the general
population of breast cancer patients, the research specifically
addressingBCYW is limited and needs further investigation.
A conceptual model for lifestyle factors in breast
cancer prognosis among young women
Despite the acknowledged differences in clinical outcomes,
tumor subtypes and treatment approaches in young women
compared with older women, specific insights into the
basic biology, epidemiology, and optimal therapeutic
strategies for BCYW are relatively sparse. Several modi-
fiable factors that have been associated with reduced risk of
developing breast cancer may also be implicated in
improved prognosis. Given the treatment-related toxicities,
and the extended window for late effects, including car-
diotoxic effects of systemic and radiation therapy [16–19],
bone health issues [20], and elevated risk of second pri-
mary cancers [21, 22], these long-term lifestyle factors
potentially offer particularly significant benefits in BCYW
(Fig. 2). We propose a biologic model to identify three
main lifestyle-related factors in BCYW prognosis research
(Fig. 1). We hypothesize that positive energy balance
(obesity and physical inactivity), specific dietary factors,
and inflammatory triggers contribute to a pro-inflammatory
state that is conducive to increased risk of progression,
recurrence, and decreased survival after a breast cancer
diagnosis in young women. The extended period of
potential post-diagnostic survival and the lower burden of
competing mortality risks in young women provide a
context in which lifestyle modification could have a sub-
stantial impact on long-term mortality and morbidity.
All of the factors included in our review affect the
hypothesized pro-inflammatory state, and our conceptual
model seeks to integrate the impact of lifestyle factors that
have been implicated in modifying clinical outcomes fol-
lowing a diagnosis of breast cancer (Fig. 1). The contributors
to a pro-inflammatory state (red labels) and the potentially
beneficial impacts (green labels) of diet, physical activity,
sleep, and non-steroidal anti-inflammatory drugs (NSAIDs)
are included. The conceptual model provides a framework for
this review as well as a roadmap for future research to inte-
grate diet, nutrient levels, shared signaling between obesity
and inflammation, and potential lifestyle interventions. Each
of the three main areas is reviewed in the sections below.
Clinical context
The cumulative incidence of breast cancer rises exponen-
tially until age 40 years and then rises more linearly with
age [23]. Incidence rates among young women vary by
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geographic region, and ethnicity with the highest rates
reported among Western populations [24, 25] and among
black women [26]. Clinical outcomes of BCYW are rela-
tively poor compared to older women diagnosed with
breast cancer. Early age-of-onset increases the risk of
contralateral breast cancer [27], local [28–30], and distant
recurrence [23]. The European Organisation for Research
and Treatment of Cancer (EORTC) trials showed a hazard
ratio (HR) of 2.8 (95 % confidence interval [CI] 1.4–5.6)
for local recurrence in patients \35 years compared to
those [50 [28]. Voogd et al. [31] examined two large
clinical trials of women with stage I–II breast cancer and
reported a dramatically increased risk (HR = 9.2, 95 % CI
3.7–23.0) of local recurrence in women\35 years of age
compared to women age C65 years.
Young age at diagnosis is associated with reduced sur-
vival, even after controlling for differences in the distri-
bution of prognostic features between older and younger
women with breast cancer [9, 32–35]. A retrospective
evaluation of outcomes among more than 200,000 women
with breast cancer in the SEER database found that women
aged\40 were 39 % more likely to die of their disease
when compared to those aged C40 (HR = 1.39, 95 % CI
1.34–1.45). The largest differences in mortality were seen
among women with early-stage disease. Women\40 were
more likely to die of stage I or II cancers than older women
(44 and 9 %, respectively) [36]. Similar associations
between reduced survival in younger, early-stage patients
have been observed in other cohorts of BCYW [37, 38].
Furthermore, survival rates were comparatively lower
across all histologic subtypes and stages for women
\40 years of age [39]. According to SEER data, for cases
diagnosed between 1975 and 2000, the 5-year relative
survival rate was 84–86 % overall among women aged
45–80 years, but 80, 76, 72, and 75 % among women aged
35–39, 30–34, 25–29, and 20–25 years, respectively [40].
The absolute benefits of treatment, whether local or
systemic, tend to be larger in younger women because of
the higher proportion of aggressive disease [41, 42], but
few trials have specifically evaluated treatment selection
for younger women; the median age of patients in most
randomized controlled trials (RCTs) is about 55 years [41–
45]. Younger patients tend to have fewer comorbidities and
better tolerance of treatment toxicities and, consequently,
are often treated more aggressively. Most women are
treated with breast-conserving surgery (BCS) followed by
Fig. 1 Proposed biologic
model depicting how multiple
lifestyle risk factors may
influence breast cancer
prognosis through a pro-
inflammatory state including
important exposures, pathways,




red arrows indicate potentially
detrimental factors. (Color
figure online)
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radiation therapy (RT) [41, 44, 46–49], but population-
based analyses have shown higher rates of mastectomy for
BCYW compared to older women with similar stage dis-
ease [46, 47]. Residual concerns regarding higher overall
recurrence rates, a longer potential life span requiring
ongoing follow-up/surveillance, and the risk of radiation-
induced second primary tumors in young women [50] may
contribute to provider recommendations or patient prefer-
ence for mastectomy in spite of evidence that outcomes
following BCS ? RT of mastectomy are equivalent, even
among BCYW [31, 51–54]. The 2015 National Compre-
hensive Cancer Network (NCCN) breast cancer manage-
ment guidelines no longer cite young age (\35 years) as an
indication for mastectomy, as was the case in the earlier
1997 NCCN guidelines [55]. However, young women
(\40 years) were almost four times more likely to receive
bilateral mastectomy than women aged 50–64 years (OR
3.81; 95 % CIs 3.55–4.08) [56].
Younger women also tend to receive more intensive
radiation and systemic therapy despite an international
expert panel advocating that young age alone should not be
sufficient justification for aggressive therapy [15]. Whole
breast RT plus a supplementary ‘‘boost’’ dose to the pri-
mary site is routinely administered following BCS in
younger women [57] because RCTs have shown that they
experience the largest absolute improvements in local
control [58]. The majority of young women with breast
cancer are candidates for chemotherapy and anti-estrogen
therapy (for ER-positive disease, usually with tamoxifen)
for at least 5 years [3, 15, 42]. Young women increasingly
receive neoadjuvant chemotherapy prior to definitive local
therapy to downstage disease and, in some cases, to facil-
itate BCS where mastectomy might have otherwise been
indicated [57]. In addition, the tumor subtypes most com-
monly found in young women are more likely to respond to
neoadjuvant chemotherapy and provide an in vivo evalu-
ation of response to systemic therapy. The higher fre-
quency of HER2 over-expression, TNBC, and BRCA
mutations in BCYW results in these women being offered
novel combinations of systemic therapeutic agents more





Positive energy balance, as a consequence of excess caloric
intake and/or insufficient energy expenditure, results in
increased adipose tissue leading to overweight and/or
obesity. Both obesity [59] and physical inactivity [60]
Fig. 2 Potential period for
lifestyle modification to impact
outcomes in breast cancer
patients according to age at first
diagnosis
Compared to women at the
median age of diagnosis, young
women (\40 years) have
approximately twice the
duration of post-diagnostic/post-
treatment life during which their
risk of disease and treatment-
related consequences are
elevated. The opportunity to
mitigate these effects through
lifestyle modification is much
greater for younger women
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increase the risk of breast cancer development in older
women and progression at all ages. Increased risks for
overall mortality and breast cancer-specific mortality
associated with increasing body mass index (BMI; e.g.,
HR = 1.41, 95 % CI 1.29–1.53) [61] or waist–hip ratio
(HR = 1.31, 95 % CI 1.08–1.58) were reported in a recent
meta-analysis [62]. Larger effect sizes for breast cancer
mortality are associated with obesity among pre-meno-
pausal (HR = 1.75, 95 % CI 1.26–2.41) compared to post-
menopausal women (HR = 1.34, 95 % CI 1.18–1.53) [61].
One of the biologic mechanisms through which obesity
could affect cancer survival is by altering the insulin
resistance (IR) pathway [63]. Homeostatic model assess-
ment (HOMA) is a method for assessing b-cell function
and IR from basal (fasting) glucose and insulin or C-pep-
tide concentrations [64]. Although no data exist specifically
for young women, increasing HOMA-IR has been associ-
ated with a positive trend for breast cancer recurrence in
ER-/PR-negative patients (p for trend = 0.087) and an
inverse trend in ER-/PR-positive patients (p for
trend = 0.081) among a general population of breast can-
cer patients [65]. In a multiethnic cohort of 527 women
with breast cancer [Health, Eating, Activity, and Lifestyle
(HEAL) Study], increasing HOMA scores were associated
with reduced breast cancer survival (HR = 1.12, 95 % CI
1.05–1.20) [66].
Excess adiposity may also impact cancer survival by
altering levels of circulating adipokines, particularly ele-
vating leptin, and decreasing adiponectin [67, 68]. Leptin
and adiponectin are secreted by adipose tissue and play
opposing endocrine, paracrine, and autocrine roles in the
development and progression of breast cancer [69–72].
High ([median) levels of adiponectin were associated with
significantly decreased mortality in the HEAL study
(HR = 0.39, 95 % CI 0.16–0.95) [66]. Adiponectin indu-
ces apoptosis in dose-dependent manner and interacts with
estrogen receptors to reduce breast cancer cell growth [73–
77]. To our knowledge, the effects of these pathways (in-
sulin resistance and adipokines) have not been evaluated
specifically among BCYW; however, differences in sur-
vival associated with BMI may be mediated by these
pathways in BCYW.
Physical activity
Physical activity has been consistently associated with
improved survival and other breast cancer-specific out-
comes in breast cancer patients [63, 78]. While these epi-
demiologic studies have included women under 40 years of
age, only one study focused specifically on young women
(n = 717) with 251 breast cancer deaths after a median
follow-up of 10.4 years [79]. The risk of breast cancer-
specific mortality for young active women (aged 20–54,
C5 h of recreational activity per week) was reduced
compared to young inactive women (HR = 0.78 (95 % CI
0.45–1.34)) [80]. This estimate was adjusted for cancer
stage and BMI, but not for treatment. A recent meta-
analysis reported pooled data from four prospective cohort
studies of older/post-menopausal women [81]; those
engaging in at least 10 MET-hours (MET = metabolic
equivalent) of physical activity per week had a 27 %
reduction in all-cause mortality (n = 1,468 events,
HR = 0.73, 95 % CI 0.66–0.82) and a 25 % reduction in
breast cancer-specific mortality (n = 971 events, HR =
0.75, 95 % CI 0.65–0.85) compared with women per-
forming \10 MET-hours/week [81]. The magnitude of
effect in BCYW is unknown. No studies have examined the
role of sedentary behavior (commonly conceptualized as
sitting time) in breast cancer survival, despite its emer-
gence as a distinct risk factor for breast cancer separate
from the beneficial effects of physical activity [82].
In the only randomized controlled trial to date, Cour-
neya et al. [83] reported an exploratory follow-up of breast
cancer outcomes in 242 breast cancer patients randomized
to supervised exercise (aerobic or resistance) or usual care
during adjuvant chemotherapy. After an 8-year follow-up,
the overall risk of a disease-free survival event for the
exercise groups was reduced, although the difference was
not significant [HR = 0.68 (95 % CI 0.37–1.24)]. This risk
reduction was slightly lower for women under 50 years of
age (HR = 0.77, 95 % CI 0.32–1.84). Interestingly, there
did not appear to be any suggestion of benefit for women
with TNBC (HR = 1.25, 95 % CI 0.40–3.95), but there
was for women with HER2? breast cancer, although
nonsignificant (HR = 0.21, 95 % CI 0.04–1.02). These
data suggest a potentially complex effect of exercise on
breast cancer outcomes in BCYW that may vary by breast
cancer subtype.
Several biologic mechanisms have been proposed for
the beneficial effects of physical activity in cancer pro-
gression including changes in BMI and adiposity which are
likely to impact the biologic pathways discussed above as
well as altered levels of estrogens, androgens, sex hor-
mone-binding globulin, and reduced levels of inflammatory
markers [84].
Inflammation-related factors
Inflammation represents a complex network of biologic
responses and pathways mediated by cytokines, lympho-
cytes, acute-phase proteins, prostaglandins, and many other
cellular components. Inflammation plays a pivotal role in
the development and progression of breast cancer [85] and
is considered a hallmark of cancer [86]. Exposures that
increase levels of inflammation and subsequent biomarkers
Cancer Causes Control (2016) 27:459–472 463
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of inflammation are associated with reduced overall sur-
vival among breast cancer patients [87]. The subsequent
sections review several inflammatory factors and their
potential roles in BCYW survival.
Cytokines
Inflammatory cytokines including interleukins (IL-1b, IL-
2, IL-6, IL-8, IL-12), tumor necrosis factor alpha (TNF-a),
and interferon gamma (IFN-c) are key inflammatory
mediators of interest in breast cancer progression. Changes
in inflammatory cytokine levels are observed in obese
individuals and may represent critical mediators between
energy imbalance and breast cancer survival [88]. Elevated
circulating levels of IL-6 have been associated with
reduced breast cancer survival [89] and increased tumor
burden [90]. IL-8 is highly expressed by tumor and stromal
cells, and its expression in breast tumor cells is stimulated
by TNF-a and/or IL-1b, two other important inflammatory
cytokines in cancer development [91, 92]. The mean sur-
vival time from first metastasis was significantly lower in
breast cancer patients with reduced circulating IL-2 con-
centrations compared to those with normal IL-2 values,
irrespective of response to therapy and dominant metastasis
sites [93]. Serum levels of TNF-a have been found to be
significantly predictive of breast cancer survival, particu-
larly among women with HER-2 over-expression [94, 95].
T lymphocytes
The immune system may play an important role in tumor
control through both the elimination of immunogenic
tumor cells (immunosurveillance) and to promote the out-
growth of less immunogenic tumor cell variants (immune
editing) [96]. In breast cancer, the relationship between
host defense mechanisms and clinical outcomes has been
debated for some time [97]. T cells play an integral role in
the inflammatory response. For example, T-helper (Th)1
cells produce cytokines IL-2, IFN-a˜, and TNF-a´, all of
which are important in viral clearance and tumor surveil-
lance. In contrast, Th2 cells produce IL-4, IL-5, and IL-13
which help to activate eosinophils and mast cells. Mean-
while, CD8-expressing cytotoxic T lymphocytes (CTLs)
secrete cytokines and target the cells with which they
interact for destruction [98]. Therefore, both groups of T
cells may mediate processes integral to inflammation,
carcinogenesis, and cancer progression [99]. An analysis of
1,334 tumors showed that a high total CD8? CTL count
was an independent prognostic factor associated with
longer survival in early-stage breast cancer patients
(p\ 0.001) [100]. The presence of a CD8? lymphocytic
infiltrate in breast cancer tissue is associated with improved
outcome, further indicating that the immune system
participates in the control and elimination of tumor cells
[101, 102]. Conversely, high levels of CD4? CTL infil-
tration have typically been correlated with reduced overall
survival [103]. No studies have directly examined the
prognostic impact of T cell levels in BCYW, but T cell
infiltrate may be particularly significant in TNBC
which are more common in BCYW [99, 104]. The
immunomodulatory subtype of TNBC [105] has been
characterized by elevated expression of genes involved in
T cell function, immune transcription, interferon (IFN)
response, and antigen processing [106]. Immunotherapy
and lymphocytic response to therapy are of interest in
breast cancer treatment [107, 108], but the prognostic
effects and potential for immune-based intervention have
not yet been investigated in BCYW.
Acute-phase proteins
Acute-phase proteins are produced by the liver in response
to inflammatory cytokines. Elevated levels of serum amy-
loid A (SAA) and C-reactive protein (CRP) are associated
with significantly increased risk of death among breast
cancer patients (HR = 3.15, 95 % CI 1.73–5.65 and
HR = 2.27, 95 % CI 1.27–4.08, respectively) [109, 110].
However, it is unclear whether these proteins have direct
functional roles or simply reflect an overall inflammatory
response.
NSAID use
Prostaglandins are lipid autacoids derived from arachidonic
acid, an omega-6 fatty acid. They both sustain homeostatic
functions and mediate pathogenic mechanisms, including
the inflammatory response [111]. Prostaglandins are syn-
thesized by cyclooxygenases COX-1 and COX-2. Elevated
COX-2 expression has been consistently associated with
advanced disease stage, reduced survival, and poor prog-
nosis among breast cancer patients [112–114]. The poten-
tial anti-metastatic properties of aspirin have been reported
for several decades [115, 116], but it is only recently that
significant epidemiologic research has focused on the role
of aspirin and other NSAIDs in the prognosis of breast
cancer patients [117]. Existing literature suggests that the
proportion of breast cancer patients regularly using
NSAIDs varies from 30 to 50 % (with varying definitions
of regular use). Recent data indicate that post-diagnostic
NSAID use is associated with reduced likelihood of breast
cancer recurrence and breast cancer-specific mortality
among the general population of breast cancer patients
[118–122]. Although no previous studies have focused
specifically on the impact of NSAIDS on survival among
BCYW, those studies that examined survival differences
across pre- and post-menopausal status have not reported
464 Cancer Causes Control (2016) 27:459–472
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significant differences although statistical power was gen-
erally limited. However, Zhang et al. [123] reported that
the reduced risk of breast cancer (OR = 0.62; 95 % CI
0.41-0.94) associated with NSAID use was restricted to
pre-menopausal women only. The dearth of studies
examining the impact of NSAID use on BCYW is likely
attributable to both the relative rarity of BYCW and indi-
cations for chronic NSAID use among young women.
Sleep
Sleep disturbance and insomnia are common and often
persistent behavioral comorbidities following a diagnosis
of cancer [124]. Most sleep and breast cancer research,
including circadian disruption, has focused on the impact
of sleep quality and quantity on breast cancer risk [125],
but there is increasing evidence that these factors may
impact both quality of life and survival outcomes after a
breast cancer diagnosis [125, 126]. Sleep affects many of
the inflammatory factors that are implicated in our pro-
posed biologic model (Fig. 1) such as cytokine production,
adipokine production, and immune responses [127, 128].
Furthermore, sleep disturbance, insomnia, and sleep
restriction are associated with pro-inflammatory responses
[129] and these responses are particularly pronounced in
women. The methodological challenges of examining the
inflammatory and immune consequences of compromised
sleep are substantial [128]. However, chronic sleep cur-
tailment has been associated with elevated inflammatory
activity [130, 131] although no studies have specifically
investigated these responses in young women with breast
cancer.
Dietary intake
There is considerable evidence regarding the role of dietary
intake in breast cancer etiology, but relatively little
research has focused on the role of these exposures in
prognosis, particularly among BCYW. The World Cancer
Research Fund states that ‘‘…in the absence of stronger
evidence, we believe the best advice for cancer survivors is
to follow our Recommendations for Cancer Prevention’’
[105]. There is some evidence to suggest that high post-
diagnostic fruit, vegetable, whole grain, and protein intake
decrease the risk of mortality following breast cancer,
while high animal fat intake increases the risk [132, 133].
The role of specific dietary components, including vita-
mins, fatty acids, and alcohol consumption, or overall
dietary patterns, have also been evaluated, but findings are
inconclusive [133–137]. Well-designed studies are needed
to address the critical gap in the current literature regarding
the role of diet in breast cancer survival, particularly
among young women. In the subsequent sections, we
review several dietary factors that may modify survival
among young women with breast cancer. Each factor has
been associated with altered breast cancer risk or survival
in breast cancer cohorts not restricted by age. Where rel-
evant, we relate these dietary factors to our proposed bio-
logic model (Fig. 1).
Dietary fat
Dietary fat intake has been extensively researched in
relation to breast cancer risk, but the evidence remains
inconclusive [138]. Dietary fat intake might influence risk
of breast cancer through the promotion of oxidative stress,
hormonal dysregulation, or inflammatory signaling [139].
These same mechanisms are implicated in breast cancer
progression and recurrence, but few studies have investi-
gated the impact of dietary fat intake on breast cancer
outcomes and none have specifically investigated their
effects on BCYW.
The literature on dietary fat and breast cancer survival
has recently been thoroughly reviewed elsewhere [139].
Several epidemiologic studies have analyzed the associa-
tion between pre-diagnostic and post-diagnostic fat intake
on survival in breast cancer patients, with total dietary fat
intake the most common measure. Fewer studies have
considered the contribution of subtypes of fat (e.g., transfat
and saturated fat) in breast cancer patients although these
studies have reported the strongest associations with mor-
tality [140]. More studies have investigated overall survival
than breast cancer-specific survival, and the reported
associations with overall survival are typically stronger
than that for breast cancer-specific mortality. In keeping
with our biologic model, the caloric density and pro-in-
flammatory effects of dietary fat could adversely affect
outcomes in young women with breast cancer through
multiple biologic processes (Fig. 1). Many of the studies
investigating the role of dietary fat intake on breast cancer
outcomes have reported associations that fail to reach sta-
tistical significance, and the point estimates are too
inconsistent to provide a clear consensus [139]. However,
the lack of published research regarding the role of fat
intake in BCYW combined with both the potential bene-
ficial and detrimental impacts of fat subtypes, presents an
opportunity to address the impact of fat intake on post-
diagnostic outcomes in BCYW.
Vitamin D
Vitamin D is mostly synthesized in the skin by ultraviolet
B radiation (only in the summer at higher latitudes), while
dietary intake and supplements also contribute to overall
vitamin D status, particularly in the winter in northern
Cancer Causes Control (2016) 27:459–472 465
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populations. The evidence to support an inverse association
between breast cancer risk and vitamin D status is complex
and uncertain [141], but there is increasing evidence that
vitamin D status may be an important factor in breast
cancer survival [142]. There are several plausible mecha-
nisms whereby vitamin D may influence the phenotype of
the primary tumor and potentially improve outcomes.
Vitamin D exhibits pro-differentiation and anti-prolifera-
tive properties [143]. Accumulating evidence implicates
suboptimal vitamin D status in the development of
inflammatory and immunological conditions [144], com-
patible with the observed immunosuppressive and anti-in-
flammatory activity of 1,25-dihydroxyvitamin D, the active
metabolite of vitamin D [145]. No previous studies have
examined the impact of vitamin D status in BCYW, and the
impact on pre- versus post-menopausal women has been
inconsistent. However, a few studies have identified dif-
ferences in outcome between tumor phenotypes in pre- and
post-menopausal women associated with vitamin D status.
Goodwin et al. [142] reported that low serum 25-hydrox-
yvitamin D concentration (\50 nmol/L) was associated
with higher tumor grade at diagnosis, increased risk of
distant recurrence (HR = 1.94, 95 % CI 1.16–3.25), and
increased risk of breast cancer-specific death (HR = 1.73,
95 % CI 1.05–2.86) compared with patients with levels
[72 nmol/L. Similarly, Yao et al. [146] reported that low
vitamin D status was associated with the occurrence of
higher-grade tumors in pre-menopausal women only.
Peppone et al. [147] observed an increased proportion of
ER-negative tumors in the vitamin D-deficient group
(\20 ng/mL) compared to patients with higher levels. Not
all studies have suggested higher serum vitamin D post-
diagnosis is associated with better outcomes [148, 149].
These conflicting results are partly attributable to insuffi-
cient statistical power, non-population-based sampling, and
suboptimal exposure assessment.
Phytoestrogens
The two main classes of phytoestrogens (plant compounds
with non-steroidal estrogen-like structures and activities)
are isoflavones and lignans. Isoflavones are found primarily
in soy foods, while lignans are found in low concentrations
in fiber-rich foods such as grains, legumes, seeds, fruits/
vegetables, and in high concentration in flaxseeds [150].
Many supplements also contain high concentrations of
isoflavones and lignans [151]. For over a decade,
researchers have reported that dietary phytoestrogen intake
is associated with reduced breast cancer risk, possibly due
to demonstrated beneficial effects on proliferation, apop-
tosis, angiogenesis, as well as estrogen receptor mediated
and other activities, including a range of anti-inflammatory
effects [152–158]. However, only recently has the
association between post-diagnostic phytoestrogen intake
with breast cancer recurrence and mortality been investi-
gated. Overall, most studies suggested that post-diagnosis
intake improved prognosis [159–164], but findings strati-
fied by menopausal status, if reported, have been incon-
sistent [159, 160, 162]. Most of the six prognostic studies
included predominately post-menopausal women [159,
161, 163, 164], leaving a paucity of information regarding
phytoestrogen intake and prognosis among BCYM. The
largest soy/isoflavone study found a significantly reduced
risk of recurrence and breast cancer mortality combined
(HR = 0.77, 95 % CI 0.60–0.98), with no difference by
menopausal status. Two meta-analyses reported a statisti-
cally significantly reduced risk of recurrence that was
restricted to post-menopausal women [165, 166]. A
reduced risk of all-cause and breast cancer-specific mor-
tality was also reported [165, 166]. No prognostic study has
assessed post-diagnostic lignan intake, although one study
of post-menopausal women evaluated serum levels of
enterolactone—a lignan biomarker [164]. Higher serum
enterolactone levels were associated with a significantly
reduced risk of death (HR = 0.58, 95 % CI 0.34–0.99) and
a nonsignificantly reduced risk of recurrence (HR = 0.62,
95 % CI 0.35–1.09). Since prognosis varies by tumor and
treatment characteristics, future studies must control for
these factors [164, 166].
Folate
Folate is a naturally occurring, water-soluble vitamin B
[167]. Mandatory fortification of food with folic acid,
implemented to reduce the incidence of neural tube defects,
has resulted in a dramatic increase in folate intake at the
population level [168, 169]. Folate plays an important role
in DNA synthesis and methylation by mediating the
transfer of single-carbon molecules for various biologic
reactions [170, 171]. The mechanism by which folate
intake or status might impact BCYW and the direction of
the association with outcomes is uncertain. Both DNA
synthesis and DNA methylation could promote or suppress
cancer progression [170, 171]. Given its important biologic
role, there has been intense interest in the cancer-protective
effects of folate [171, 172]. Although some literature
suggests an inverse association between folate status (di-
etary intake and/or blood levels) and the risk of developing
cancer [173], contrasting evidence also supports that high
folate levels may promote cancer progression and actually
increase the risk of some cancers, including breast cancer
[173–175]. High folate intake may increase breast cancer
risk by promoting the progression of existing (pre-)neo-
plastic lesions, by expanding the breast stem cell popula-
tion or by preventing terminal differentiation in ductal cells
[173, 175, 176]. Since a high proportion of cancer
466 Cancer Causes Control (2016) 27:459–472
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survivors consume supplements containing folic acid [177–
179], the role of folate in breast cancer prognosis needs
clarification.
To date, eight studies have evaluated the relationship
between dietary or plasma folate levels and survival after
breast cancer and findings have been inconsistent [133,
180–186]. Four studies found no association [133, 181,
182, 185], three reported a significant inverse relationship
[180, 183, 184], and a recent study reported a harmful
effect of high folate status on breast cancer prognosis,
specifically in ER-/PR- tumors [186]. However, these
studies included mostly post-menopausal women and none
evaluated the impact of folate in patients diagnosed at a
young age. It is also unknown whether the relationship
between folate status and survival varies by folate
receptor alpha (FRa) expression of the tumor. Positivity
for FRa has previously been associated with the occur-
rence of TNBC and poor prognosis [187]. Interestingly,
FRb was recently identified as a marker for a pro-in-
flammatory subset of monocytes [188]. Both elevated
folate and folate insufficiency may induce inflammatory
processes [189].
Alcohol
The role of alcohol consumption in breast cancer devel-
opment and progression generates great public interest and
scientific debate. The exact mechanism of action remains
to be elucidated, but alcohol is proposed to cause tissue
damage and cancer progression is through the formation of
acetaldehyde [190]. Acetaldehyde is the primary product of
ethanol oxidation, and its rate of formation is determined
by the rate of nicotinamide adenine dinucleotide oxidation
through mitochondrial electron transport [191]. Inefficient
metabolism or excretion of ethanol and acetaldehyde
results in the formation of reactive oxygen species, notably
superoxide [192], which affects carcinogenesis through an
inflammatory response.
The association between alcohol consumption and
prognosis has not been directly evaluated in BCYW.
However, a recent meta-analysis of prospective cohort data
showed that for pre-menopausal women, high levels of
alcohol consumption were associated with increased risk of
breast cancer recurrence (HR = 1.52, 95 % CI 1.21–1.90)
[136]. Another meta-analysis reported a small reduction in
all-cause mortality associated with moderate consumption
in ER? patients and a reduction in breast cancer-specific
mortality with moderate consumption in ER-negative
breast cancer [193]. The associations overall and across
relevant subgroups require additional study because of the
high prevalence of the exposure among young women in
western populations (54.6 % among women 18–44 in the
USA) [194].
Conclusions and strategies for additional research
Given the high rates of recurrence and poorer survival in
BCYW, there is an urgent need to optimize lifestyle
advice to improve outcomes for these women. Modifiable
lifestyle factors offer an opportunity to complement
conventional therapies provided to these women. The
majority of the factors included in this review show
common etiologic links in the progression of breast can-
cer through altered pathways ultimately leading to a pro-
inflammatory state. We acknowledge that the list of fac-
tors is not exhaustive; however, the aim of this review is
to provide an integrated view of the inter-relationship
between the most promising candidate modifiable factors.
In doing so, we provide a conceptual model for the inter-
play between factors and their possible contributions to
cancer progression and survival. This literature review has
highlighted the paucity of data on the effect of these
modifiable factors on breast cancer prognosis among
young women. We propose that the potential for an
impact on reducing recurrence and improving survival
may be considerable. Additional research on this area will
provide directions for lifestyle and clinical interventions
that support beneficial behavioral change to improve
outcomes in young women diagnosed with breast cancer.
Future investigations should aim to maximize the inte-
gration of factors so that the relative impacts of multiple
lifestyle factors can be assessed both independently and in
combination. Furthermore, molecular and genetic markers
may help to determine potentially relevant subgroups
likely to experience maximal or minimal beneficial
impact. Integrated study designs with appropriate
biospecimen collections will support the assessment of
the relative contributions of these exposures to the path-
ways proposed in our biologic model focused on survival
in BCYW.
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